Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 332L4 | — |
Maladministration of AS01B adjuvant of Shingrix (without the lyophilized antigen component); Maladministration of AS01B adjuvant of Shingrix (without the lyophilized antigen component); This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number 332L4, expiry date 04-APR-2027) for prophylaxis. On 30-JUL-2025, the patient received Shingrix. On 30-JUL-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate dose of vaccine administered (Verbatim: Maladministration of AS01B adjuvant of Shingrix (without the lyophilized antigen component)) and inappropriate preparation of medication (Verbatim: Maladministration of AS01B adjuvant of Shingrix (without the lyophilized antigen component)). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. Additional Information: GSK receipt date: 08-AUG-2025 A clinical supervisor called to ask about the specific timeframe/additional vaccine administration for a valid dose of Shingrix, since five patients were potentially administered with the adjuvant alone which led to inappropriate preparation of medication and inappropriate dose of vaccine administration. Vaccination date, vaccine detail and patient demographics were obtained in this call. No further information was obtained in this call. This is 1 of the 5 cases reported by the same reporter.; Sender's Comments: US-GSK-US2025103164:Same reporter US-GSK-US2025103636:Same reporter US-GSK-US2025103162:Same reporter US-GSK-US2025103160:Same reporter